How should Selank (Intranasal) be stored and reconstituted?

Lyophilised Selank (Intranasal) stores at −20°C for 18–24 months. After reconstitution with bacteriostatic water, the solution holds at 4°C for 14–28 days. Avoid freeze-thaw cycles of reconstituted material. Travel with cold packs in insulated containers; avoid prolonged exposure above 25°C. The standard reconstitution concentration is 1–2 mg/mL depending on the vial size.

How does Selank (Intranasal) map to the hallmarks of aging?

Selank (Intranasal)'s longevity relevance maps to specific hallmarks based on its mechanism. Same Selank molecule; olfactory pathway bypasses BBB. For users tracking healthspan-relevant biomarkers across cycles, the relevant endpoints are determined by which hallmark the compound primarily targets — telomere maintenance, senescence modulation, mitochondrial biogenesis, autophagy induction, inflammaging, or epigenetic clock effects. The framework above identifies the dominant contribution.

How does Selank (Intranasal) compare to Epithalon and Thymalin?

Selank (Intranasal) (Tuftsin-derived heptapeptide (intranasal), CNS effect hours half-life, 300 mcg per spray typical dose) differs from peers in the comparison table above. The principal points of difference relative to Epithalon and Thymalin are mechanism, half-life, and target system. The full comparison is in the table above; specific stack selection depends on which dimension matters for the application.

What is the regulatory status of Selank (Intranasal)?

Selank (Intranasal) regulatory status: Unapproved (Russia approved) in the United States; WADA status not on prohibited list; research level research level investigational. Clinical access for off-label use is via compounded prescription where permissible. International regulatory status varies by jurisdiction. For healthspan and biological-age use specifically, the regulatory profile shapes which monitoring and supervision approaches are required.

What should I look for in Selank (Intranasal) sourcing and quality?

Acceptable Selank (Intranasal) certificates of analysis specify: lot-specific (not template) issuance, HPLC purity ≥98%, mass spec confirmation matching 751 Da, endotoxin testing for injectable routes, and third-party accredited laboratory issuance. Template COAs, missing endotoxin data, or vendor-internal labs are red flags. Pharmaceutical-grade compounded material is the lowest-risk supply path where accessible.

Home/ Compounds/ Selank (Intranasal)

Selank (Intranasal)

Longevity

Longevity research evaluates Selank (Intranasal) against the hallmarks-of-aging framework rather than against acute clinical endpoints. Same Selank molecule; olfactory pathway bypasses BBB. The compound's mechanism places its dominant contribution at specific hallmark layers; the question for healthspan-tracking users is whether biomarkers (epigenetic age, telomere length, inflammatory panels) move measurably across the typical 300 mcg per spray 2-3 sprays daily for 2-4 week courses cycle.

Longevity / Hallmarks of Aging Applications

Senescence ModulationCellular ReprogrammingmTOR ModulationNutrient SensingMitochondrial Biogenesis

Key Takeaways

Longevity lens: Selank (Intranasal) maps to specific hallmarks-of-aging endpoints rather than to acute clinical markers.
Mechanism: Same Selank molecule; olfactory pathway bypasses BBB.
Healthspan biomarkers: epigenetic age, telomere length, inflammatory markers, metabolic flexibility - all tracked across pre-post cycles.
Longevity protocol: cycle-based 300 mcg per spray 2-3 sprays daily for 2-4 week courses dosing; 8-12 week cycles favoured over continuous administration.
Longevity stack partners: Epithalon, Thymalin, NAD+.

Longevity / Hallmarks of Aging Mechanism

Same Selank molecule; olfactory pathway bypasses BBB. Hallmarks-of-aging mapping for Selank (Intranasal): which of the nine hallmarks does this mechanism engage? The subsections below address Selank (Intranasal)'s mapping to the hallmark framework, its effects on cellular reprogramming and gene expression, healthspan biomarker movement, and the cycle-based versus continuous dosing question that frames longevity-research protocol design.

Mapping to the hallmarks of aging

Selank (Intranasal)'s longevity relevance is best evaluated by mapping its mechanism to the hallmarks-of-aging framework. Same Selank molecule; olfactory pathway bypasses BBB. This places its dominant contribution in the integrative hallmarks (systemic and inflammatory) layer of the framework, with secondary effects on adjacent hallmarks that combine to produce the broader healthspan-relevant phenotype.

Cycle-based versus continuous dosing

Selank (Intranasal)'s longevity protocol is compatible with either cycle-based or continuous dosing depending on the broader stack. The longevity-research convention favours pulsatile and periodic interventions over indefinite continuous administration, on the principle that hormetic stimulation outperforms sustained agonism for systems-biology-relevant endpoints.

Healthspan markers and biological age

For users measuring epigenetic age, telomere length, or composite biological-age markers (Horvath, PhenoAge, GrimAge) before and after Selank (Intranasal) cycles, the question is whether the intervention measurably moves these markers. Current evidence varies by compound but the framework for evaluation is shared: paired pre-post measurement with appropriate inter-test interval.

Longevity / Hallmarks of Aging Applications

Senescence Modulation

For senescence modulation as a longevity-relevant endpoint, Selank (Intranasal) is typically run in cycle-based protocols with paired pre-post biomarker measurement. Epigenetic age tracking, telomere length, and inflammatory panels are the standard outcome measures.

Inflammaging

Inflammaging maps to one of the hallmarks of aging and is one of the dimensions on which Selank (Intranasal) is evaluated in the longevity literature. Effect size on biomarkers varies across studies; the consistent finding is direction-of-effect rather than dramatic magnitude.

Mitochondrial Biogenesis

Selank (Intranasal)'s contribution to mitochondrial biogenesis as a longevity dimension is incremental rather than dramatic, consistent with the broader picture of healthspan-relevant peptides. The compound is best understood as one layer in a multi-component longevity protocol.

Hallmarks of Aging

For hallmarks of aging as a longevity-relevant endpoint, Selank (Intranasal) is typically run in cycle-based protocols with paired pre-post biomarker measurement. Epigenetic age tracking, telomere length, and inflammatory panels are the standard outcome measures.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	Intranasal	300 mcg per spray	8–12 weeks on / 4 weeks off
Conservative starter	Intranasal	180 mcg per spray	4–6 weeks initial cycle
Longevity focus	Intranasal	300 mcg per spray	2-3 sprays daily for 2-4 week courses
Maintenance phase	Intranasal	210 mcg per spray	Ongoing with periodic pauses

Dose timing for Selank (Intranasal) is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Selank (Intranasal) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from longevity researchers.

Selank (Intranasal) + Epithalon: Identified by Khavinson in St. Pairs naturally with Selank (Intranasal)'s mechanism in longevity / hallmarks of aging protocols.
Selank (Intranasal) + Thymalin: Influences T-cell maturation and immune function. Pairs naturally with Selank (Intranasal)'s mechanism in longevity / hallmarks of aging protocols.
Selank (Intranasal) + NAD+: Coenzyme for over 500 enzymatic reactions including oxidative phosphorylation, glycolysis, fatty acid β-oxidation, and the citric acid cycle. Pairs naturally with Selank (Intranasal)'s mechanism in longevity / hallmarks of aging protocols.
Selank (Intranasal) + MOTS-c: Translocates to the nucleus under metabolic stress and activates AMPK signalling. Pairs naturally with Selank (Intranasal)'s mechanism in longevity / hallmarks of aging protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Unapproved (Russia approved)

Excellent. Mild nasal irritation possible.

Lens-specific safety considerations for longevity / hallmarks of aging use of Selank (Intranasal): Excellent. Mild nasal irritation possible. Additional longevity / hallmarks of aging monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Selank in GAD

PMID 21443549

Selank (Intranasal) vs Related Peptides

Compound	Profile	Onset	Best For
Selank (Intranasal)	Tuftsin-derived heptapeptide (intranasal)	CNS effect hours	Longevity
Epithalon	Pineal-derived tetrapeptide	Very short (minutes)	A pineal-derived tetrapeptide best known for telomerase upregulation and pineal-gland melatonin restoration in long-running rodent and human studies
Thymalin	Thymic polypeptide extract	Variable	A complex of low-molecular-weight thymic polypeptides used in Russian clinical research for decades — immunomodulation, anti-aging, and supportive care in chronic disease
MOTS-c	Mitochondrially-encoded peptide	Hours; tissue-distributed	A 16-amino-acid peptide encoded within mitochondrial DNA — discovered in 2015 and shown to regulate metabolic homeostasis, AMPK signalling, and insulin sensitivity
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

How do I know if Selank (Intranasal) is working?

Track outcome metrics that match the compound's primary mechanism: epigenetic age (DNA methylation panels), inflammatory markers (hsCRP, IL-6), metabolic flexibility (HbA1c, fasting insulin, HOMA-IR), body composition (DEXA), and subjective markers (sleep depth, recovery, well-being). Paired pre-post measurement around cycles is the standard framework.

Cycle-based or continuous dosing for longevity?

Longevity-research convention favours cycle-based and pulsatile interventions over indefinite continuous administration. Hormetic stimulation produces stronger systems-biology effects than sustained agonism for most longevity-relevant endpoints. Selank (Intranasal) fits this framework with cycle lengths typical for its compound class.

What are the long-term safety considerations?

Long-term safety data for most peptide compounds is limited to a small number of well-studied molecules with multi-decade clinical observation. For most others, the long-term framework relies on mechanism-based risk assessment plus accumulating clinical experience. Cycle-based dosing and periodic re-evaluation are appropriate for compounds without 10+ year human safety data.

When in life should I start Selank (Intranasal)?

Most longevity-relevant peptides have evidence bases centred on mid-life and later. Earlier use is theoretically reasonable for users with documented age-related markers (elevated inflammation, accelerated epigenetic age) or for compounds whose mechanism is preventative. Below age 35 the benefit for most longevity peptides is theoretical and warrants compound-specific consideration.

What is the mechanism of action of Selank (Intranasal)?

Same Selank molecule; olfactory pathway bypasses BBB. For healthspan and biological-age applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Same Selank molecule; olfactory pathway bypasses BBB. The longevity / hallmarks of aging interpretation focuses on the pathway-level detail rather than on any single high-level summary.

Should I cycle Selank (Intranasal)?

Standard cycle for Selank (Intranasal) is 8–12 weeks of 2-3 sprays daily for 2-4 week courses 300 mcg per spray dosing via intranasal, followed by a 4 week complete off-period. The off-period is calibrated to Selank (Intranasal)'s CNS effect hours half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

Clinical Protocol

Start a Selank (Intranasal) Protocol

Alukard provides physician-supervised longevity protocols with GMP-certified Selank (Intranasal) and GMP-certified compounds with biological age testing and healthspan markers.

Get Protocol

Quick Facts

Molecular weight: 751 Da
Sequence length: 7 aa
Half-life: CNS effect hours
WADA: Not on prohibited list
FDA: Unapproved (Russia approved)

Stack Partners

Epithalon

Thymalin

NAD+

MOTS-c

GHK-Cu

Research Note

All longevity / hallmarks of aging applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Selank (Intranasal) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised longevity protocols

Start Your Longevity / Hallmarks of Aging Protocol for Selank (Intranasal)

Alukard provides physician-supervised longevity protocols with GMP-certified compounds with biological age testing and healthspan markers.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised